Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 28, 2023 05:00 ET | Source: Alvotech

Alvotech Provides Update on Corporate Sustainability Framework

REYKJAVIK, Iceland, March 28, 2023 (GLOBE NEWSWIRE) -- Alvotech (Nasdaq: ALVO) (the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for...
March 28, 2023 05:00 ET | Source: Alvotech

Alvotech birtir nýjar upplýsingar um sjálfbærni og samfélagslega ábyrgð

Alvotech hefur birt nýjar upplýsingar um sjálfbærni og samfélagslega ábyrgð, þar á meðal mælikvarða umhverfis-, samfélags- og stjórnarhátta (ESG) fyrir árið 2022. „Markmið okkar er að bæta aðgengi...
March 28, 2023 05:00 ET | Source: Alvotech

Alvotech Provides Update on Corporate Sustainability Framework

Alvotech (Nasdaq: ALVO) (the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced an update to the...
March 17, 2023 09:10 ET | Source: Alvotech

Alvotech to Present Clinical Study Data for AVT04, a Proposed Biosimilar to Stelara®, at 2023 American Academy of Dermatology (AAD) Annual Meeting

Alvotech to present two posters related to pharmacokinetics and confirmatory clinical studies for AVT04 (ustekinumab), a proposed biosimilar to Stelara®Marketing applications for AVT04 have been...
March 17, 2023 09:10 ET | Source: Alvotech

Alvotech kynnir niðurstöður klínískra rannsókna á AVT04, fyrirhugaðri hliðstæðu við Stelara á ársþingi samtaka bandarískra húðsjúkdómalækna (AAD)

Alvotech kynnir niðurstöður úr rannsókn á lyfjahvörfum og klínískri rannsókn á sjúklingum fyrir AVT04 (ustekinumab), fyrirhugaða líftæknilyfjahliðstæðu við StelaraUmsóknir um markaðsleyfi fyrir AVT04...
March 17, 2023 09:10 ET | Source: Alvotech

Alvotech to Present Clinical Study Data for AVT04, a Proposed Biosimilar to Stelara®, at 2023 American Academy of Dermatology (AAD) Annual Meeting

Alvotech to present two posters related to pharmacokinetics and confirmatory clinical studies for AVT04 (ustekinumab), a proposed biosimilar to Stelara® Marketing applications for AVT04 have been...
March 01, 2023 16:30 ET | Source: Alvotech

Alvotech birtir uppgjör fyrir árið 2022 og kynnir nýjustu áfanga í rekstri félagsins

Heildartekjur ársins 2022 hækkuðu um 114% í 85,0 milljónir dollara samanborið við 39,7 milljónir dollara á árinu 2021, vegna tekna af sölu AVT02, líftæknihliðstæðu við Humira®, sem komin er á markað í...
March 01, 2023 16:30 ET | Source: Alvotech

Alvotech Reports Financial Results for Full Year 2022 and Provides Business Update

Full year 2022 total revenue, including other income, increased by 114% to $85.0 million, compared to $39.7 million in 2021, driven by both milestone revenue and product revenue from commercialization...
March 01, 2023 16:30 ET | Source: Alvotech

Alvotech Reports Financial Results for Full Year 2022 and Provides Business Update

Full year 2022 total revenue, including other income, increased by 114% to $85.0 million, compared to $39.7 million in 2021, driven by both milestone revenue and product revenue from commercialization...
February 27, 2023 19:15 ET | Source: Alvotech

Alvotech birtir uppgjör ársins 2022 þann 1. mars nk. og heldur kynningarfund 2. mars nk.

Alvotech (NASDAQ: ALVO) mun birta fjárhagsuppgjör ársins 2022 eftir lokun markaða í Bandaríkjunum, miðvikudaginn 1. mars 2023. Þá mun Alvotech halda kynningarfund fyrir fjárfesta fimmtudaginn 2. mars...